Managers / Q4 2022 · view latest →
DSC Advisors, L.P.
CIK 0001299434 · 900 NORTH MICHIGAN AVENUE, SUITE 1600, CHICAGO, IL, 60611 · (312) 915-2485
Summary
Dsc Advisors, L.P. reported $44M in U.S.-listed holdings across 17 positions for Q4 2022.
The portfolio is heavily concentrated: R1 Rcm alone accounts for 25.2% of reported value.
Compared with Q3 2022, the fund opened 0 new positions and exited 78.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $44M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| R1 RCM INC | ADDED | +647.5K | 1.00M | +$4M | $11M |
| CORAMERISOURCEBERGEN CORP | SOLD OUT | −65.0K | 0 | −$9M | $0 |
| APOAPOLLO GLOBAL MGMT INC | SOLD OUT | −73.0K | 0 | −$3M | $0 |
| AMZNAMAZON COM INC | SOLD OUT | −17.2K | 0 | −$2M | $0 |
| TSLATESLA INC | SOLD OUT | −4.8K | 0 | −$1M | $0 |
| PGPROCTER AND GAMBLE CO | SOLD OUT | −8.5K | 0 | −$1M | $0 |
| NVDANVIDIA CORPORATION | SOLD OUT | −8.3K | 0 | −$1M | $0 |
| PEPPEPSICO INC | SOLD OUT | −4.9K | 0 | −$797,000 | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | R1 RCM INC | COM | 25.17% | $11M | 1.00M |
| 2 | CVSCVS HEALTH CORPhistory → | COM | 21.16% | $9M | 98.8K |
| 3 | BMRNBIOMARIN PHARMACEUTICAL INChistory → | COM | 19.62% | $9M | 82.5K |
| 4 | ZBHZIMMER BIOMET HOLDINGS INChistory → | COM | 18.32% | $8M | 62.5K |
| 5 | GOOGALPHABET INC | CAP STK CL C · CAP STK CL A | 10.14% | $4M | 49.8K |
| 6 | EHTHEHEALTH INC | COM | 0.83% | $363,000 | 75.0K |
| 7 | MSFTMICROSOFT CORP | COM | 0.82% | $356,373 | 1.5K |
| 8 | VVISA INC | COM CL A | 0.65% | $281,307 | 1.4K |
| 9 | METAMETA PLATFORMS INC | CL A | 0.63% | $272,209 | 2.3K |
| 10 | MAMASTERCARD INCORPORATED | CL A | 0.62% | $270,882 | 779 |
| 11 | VYNE THERAPEUTICS INC | COM | 0.54% | $235,500 | 1.57M |
| 12 | AAPLAPPLE INC | COM | 0.53% | $231,016 | 1.8K |
| 13 | ACNACCENTURE PLC IRELAND | SHS CLASS A | 0.48% | $209,203 | 784 |
| 14 | BRK/BBERKSHIRE HATHAWAY INC DEL | CL B NEW | 0.48% | $208,199 | 674 |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2024 | $11M | 19 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $30M | 24 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $63M | 34 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $61M | 32 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $78M | 33 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $67M | 31 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $115M | 24 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $44M | 17 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $97M | 97 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $100M | 113 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $290M | 132 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $129M | 72 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $98M | 74 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $138M | 74 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $161M | 85 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $121M | 51 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $149M | 49 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $91M | 37 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $102M | 35 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $209M | 88 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $506M | 97 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $569M | 85 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $544M | 81 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $826M | 78 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- DSCQG PR LLC028-18129
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.